Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.79 |
| ▸ | TOP1 known ✓ | P11387 | 3/20 | 0.62 |
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.62 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.51 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.48 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | BLM | P54132 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.79 |
| ▸ | RECQL | P46063 | 1/20 | 0.79 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.79 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL38685 | 1.00 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL29728780 | 1.00 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL6850585 | 1.00 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL4538254 | 0.99 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL15545820 | 0.99 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL4950608 | 0.99 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL29466902 | 0.99 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL1059266 | 0.99 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hoechst 33258 SCHEMBL6942659 | 0.94 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL15969230 | 0.94 | ALDH1A1 (0.90) | ALDH1A1SMN1; SMN2MAPTMEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931713-B2 | Oligonucleotide data storage on solid supports | Global Life Sciences Solutions Operations UK Ltd (GB) | 2024-03-19 | — | — | US | disclosed |
| US-20230167197-A1 | ANTI-CERAMIDE ANTIBODIES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-01 | — | — | US | disclosed |
| CN-115811987-A | Anti-ceramide antibodies | 纪念斯隆凯特琳癌症中心 | 2023-03-17 | — | — | CN | disclosed |
| EP-4121110-A1 | ANTI-CERAMIDE ANTIBODIES | Memorial Sloan Kettering Cancer Center (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188770-A1 | ANTI-CERAMIDE ANTIBODIES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20170151545-A1 | OLIGONUCLEOTIDE DATA STORAGE ON SOLID SUPPORTS | Global Life Sciences Solutions Operations UK Ltd (GB) | 2017-06-01 | — | — | US | disclosed |
| WO-2015090879-A1 | OLIGONUCLEOTIDE DATA STORAGE ON SOLID SUPPORTS | GE HEALTHCARE UK LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| US-20120045501-A1 | CONNEXIN ENHANCES CHEMOTHERAPY-INCLUDED APOPTOSIS IN HUMAN CANCER CELLS INHIBITING TUMOR CELL PROLIFERATION | NORTHWEST HOSPITAL (US) | 2012-02-23 | — | — | US | disclosed |
| EP-1729788-B1 | RESTENOSIS THERAPY USING MESENCHYMAL STEM CELLS | BOSTON SCIENT LTD (BB) | 2009-11-25 | — | — | EP | disclosed |
| US-20080138337-A1 | CONNEXIN ENHANCES CHEMOTHERAPY-INDUCED APOPTOSIS IN HUMAN CANCER CELLS INHIBITING TUMOR CELL PROLIFERATION | NORTHWEST HOSPITAL (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2001050848-A2 | CLONAL PROPAGATION OF PRIMATE OFFSPRING BY EMBRYO SPLITTING | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-1017421-A1 | METHOD AND COMPOSITIONS FOR HEALING TISSUE DEFECTS AND INDUCING HYPERVASCULARITY IN MAMMALIAN TISSUE | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999061581-A2 | SPHINGOSINE KINASE, CLONING, EXPRESSION AND METHODS OF USE | OFFICE OF THE DEAN OF RESEARCH AND GRADUATE EDUCATION (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999007844-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF RESTENOSIS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0888458-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | Sloan-Kettering Institute For Cancer Research (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5821072-A | SCREENING PROTEIN KINASE C INHIBITORS CAPABLE OF POTENTIATING APOPTOSIS IN TUMOR CELLS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-10-13 | — | — | US | disclosed |
| WO-1998039035-A1 | METHOD AND COMPOSITIONS FOR HEALING TISSUE DEFECTS AND INDUCING HYPERVASCULARITY IN MAMMALIAN TISSUE | THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY (US) | 1998-09-11 | — | — | WO | disclosed |
| US-5744499-A | Apoptosis-modulating factors influencing the intracellular concentration of methional/malondialdehyde | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-04-28 | — | — | US | disclosed |
| WO-1997030174-A1 | COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1990013627-A1 | IN VITRO MATURATION OF BOVINE OOCYTES | GRANADA BIOSCIENCES, INC. (US) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138337-A1 | CONNEXIN ENHANCES CHEMOTHERAPY-INDUCED APOPTOSIS IN HUMAN CANCER CELLS INHIBITING TUMOR CELL PROLIFERATION | GJA1, GJB2, BCL2 | GLA 4763/4885TOP1 87/4885TOP2A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.